186 related articles for article (PubMed ID: 34435932)
1. The 13-valent pneumococcal conjugate vaccine (PCV13) does not appear to provide much protection on combined invasive disease due to the six PCV13 non-PCV7 serotypes 1, 3, 5, 6A, 7F, and 19A in Kuwait during 2010-2019.
Mokaddas E; Syed S; Albert MJ
Hum Vaccin Immunother; 2021 Nov; 17(11):4661-4666. PubMed ID: 34435932
[TBL] [Abstract][Full Text] [Related]
2. Effect of the introduction of pneumococcal conjugate vaccines on serotype prevalence in Kuwait and Saudi Arabia.
Mokaddas EM; Shibl AM; Elgouhary A; Elsobky M
Vaccine; 2018 Oct; 36(43):6442-6448. PubMed ID: 30194003
[TBL] [Abstract][Full Text] [Related]
3. Predicted serotype-specific effectiveness of pneumococcal conjugate vaccines V114 and PCV20 against invasive pneumococcal disease in children.
Ryman J; Sachs JR; Yee KL; Banniettis N; Weaver J; Weiss T
Expert Rev Vaccines; 2024; 23(1):60-68. PubMed ID: 38073483
[TBL] [Abstract][Full Text] [Related]
4. Serotype distribution and penicillin-non-susceptibility of Streptococcus pneumoniae causing invasive diseases in Kuwait: A 10-year study of impact of pneumococcal conjugate vaccines.
Mokaddas E; Albert MJ
Expert Rev Vaccines; 2016 Oct; 15(10):1337-45. PubMed ID: 27267070
[TBL] [Abstract][Full Text] [Related]
5. Impact of pneumococcal conjugate vaccines on burden of invasive pneumococcal disease and serotype distribution of Streptococcus pneumoniae isolates: an overview from Kuwait.
Mokaddas E; Albert MJ
Vaccine; 2012 Dec; 30 Suppl 6():G37-40. PubMed ID: 23228356
[TBL] [Abstract][Full Text] [Related]
6. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study.
Waight PA; Andrews NJ; Ladhani SN; Sheppard CL; Slack MP; Miller E
Lancet Infect Dis; 2015 May; 15(5):535-43. PubMed ID: 25801458
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of 13-valent pneumococcal conjugate vaccination for protection against acute otitis media caused by Streptococcus pneumoniae in healthy young children: a prospective observational study.
Pichichero M; Kaur R; Scott DA; Gruber WC; Trammel J; Almudevar A; Center KJ
Lancet Child Adolesc Health; 2018 Aug; 2(8):561-568. PubMed ID: 30119715
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the seven-valent and thirteen-valent pneumococcal conjugate vaccines in England: The indirect cohort design, 2006-2018.
Andrews N; Kent A; Amin-Chowdhury Z; Sheppard C; Fry N; Ramsay M; Ladhani SN
Vaccine; 2019 Jul; 37(32):4491-4498. PubMed ID: 31272872
[TBL] [Abstract][Full Text] [Related]
9. Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.
Steens A; Bergsaker MA; Aaberge IS; Rønning K; Vestrheim DF
Vaccine; 2013 Dec; 31(52):6232-8. PubMed ID: 24176490
[TBL] [Abstract][Full Text] [Related]
10. Prevention of pneumococcal disease among infants and children - use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine - recommendations of the Advisory Committee on Immunization Practices (ACIP).
Nuorti JP; Whitney CG;
MMWR Recomm Rep; 2010 Dec; 59(RR-11):1-18. PubMed ID: 21150868
[TBL] [Abstract][Full Text] [Related]
11. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014.
Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P
Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682
[TBL] [Abstract][Full Text] [Related]
12. Vaccine effectiveness of the 7-valent and 13-valent pneumococcal conjugate vaccines in Canada: An IMPACT study.
Ricketson LJ; Bettinger JA; Sadarangani M; Halperin SA; Kellner JD;
Vaccine; 2022 Apr; 40(19):2733-2740. PubMed ID: 35351324
[TBL] [Abstract][Full Text] [Related]
13. Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial.
Dagan R; Patterson S; Juergens C; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
Clin Infect Dis; 2013 Oct; 57(7):952-62. PubMed ID: 23804191
[TBL] [Abstract][Full Text] [Related]
14. Emerging Streptococcus pneumoniae Strains Colonizing the Nasopharynx in Children After 13-valent Pneumococcal Conjugate Vaccination in Comparison to the 7-valent Era, 2006-2015.
Kaur R; Casey JR; Pichichero ME
Pediatr Infect Dis J; 2016 Aug; 35(8):901-6. PubMed ID: 27420806
[TBL] [Abstract][Full Text] [Related]
15. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children.
Mungall BA; Hoet B; Nieto Guevara J; Soumahoro L
Expert Rev Vaccines; 2022 Feb; 21(2):201-214. PubMed ID: 34882050
[TBL] [Abstract][Full Text] [Related]
17. Pneumococcal serotype evolution in Western Europe.
Tin Tin Htar M; Christopoulou D; Schmitt HJ
BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008
[TBL] [Abstract][Full Text] [Related]
18. Health and economic burden associated with 15-valent pneumococcal conjugate vaccine serotypes in Korea and Hong Kong.
Mohanty S; Hu T; Yang G; Khan TK; Owusu-Edusei K; Sukarom I
Hum Vaccin Immunother; 2022 Nov; 18(5):2046433. PubMed ID: 35420975
[TBL] [Abstract][Full Text] [Related]
19. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries.
Hu T; Weiss T; Bencina G; Owusu-Edusei K; Petigara T
J Med Econ; 2021; 24(1):1098-1107. PubMed ID: 34461796
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae.
Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gurtman A; Gruber WC; Scott DA
J Infect Dis; 2015 Apr; 211(7):1144-53. PubMed ID: 25355940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]